New FDA-Cleared Tech Could Save Lives by Stopping Gunshot Bleeding in Seconds

Gunshot wounds are devastating, often lethal, because of the extreme blood loss they cause. But now, a groundbreaking new tech is set to change how we treat these injuries. Traumagel, a new algae- and fungi-based gel developed by Cresilon, just got FDA clearance, and it’s here to make a major impact. This isn’t just a new bandage; this gel can literally stop severe bleeding from wounds like gunshots within seconds, offering the potential to save countless lives.

A Revolutionary Approach to Hemorrhage Control

Currently, most emergency medical care for severe bleeding involves traditional methods—like packing wounds with gauze or applying pressure—both of which can be painful, slow, and not always effective. Traumagel flips that script. Applied via a 30-ml syringe, the gel flows into the wound and clots blood rapidly without the need for manual packing or intense pressure. This drastically reduces the risks for both patients and EMTs, who could otherwise be exposed to shrapnel or bone fragments while treating gunshot wounds. Plus, it’s fast: seconds to stop life-threatening hemorrhaging.

Joe Landolina, Cresilon’s founder, highlights how the product’s flowable nature helps it reach bleeding areas more effectively than traditional methods, making it a crucial new tool in situations where time is of the essence—like battlefield injuries and street-level gun violence.

Years in the Making—Finally Ready for Humans

Though Traumagel is just now receiving clearance for use in humans, the technology has been years in the making. Cresilon initially proved the product’s effectiveness in veterinary medicine, using a version called Vetigel that’s already being used in over 10,000 animal clinics. Veterinarians have used it for everything from spinal surgeries to dental cleanings, which helped build the company’s reputation and allowed them to scale the technology for human use.

Now that Traumagel has earned FDA clearance for moderate to severe bleeding, Cresilon is ready to launch it to first responders and hospitals later this year. They’ve already built a massive 33,000-square-foot manufacturing facility in Brooklyn to meet demand and are also partnering with major healthcare distributors to get Traumagel into the hands of EMTs and ER doctors nationwide.

Beyond Gunshot Wounds: Future Potential for Military and Trauma Care

Traumagel’s life-saving potential doesn’t end with gunshot wounds. The Department of Defense has already taken notice, eyeing this tech for battlefield use, where 91% of preventable deaths are due to hemorrhage. Additionally, Cresilon has been working with the Walter Reed Army Institute of Research to see if this gel could stabilize traumatic brain injuries, a project still in preclinical trials.

Although research is still ongoing for some of these applications, the possibilities are huge. With further testing, Traumagel could become a standard tool for saving lives in high-stakes trauma situations—from soldiers in combat to civilians on the street.

A Step Toward Safer, Faster Medical Response

What makes Traumagel so exciting isn’t just its cutting-edge technology but its simplicity. While the learning curve was steep for veterinarians using Vetigel on animals of all shapes and sizes, Traumagel for human use is far more straightforward. Landolina calls it “close to point and shoot,” making it easy for first responders to adopt quickly.

In a world where gun violence and traumatic injuries are on the rise, Traumagel’s launch later this year could change the game for emergency care. This tech isn’t just the future of wound treatment—it’s here, and it’s about to make a massive difference.

Support and Look Forward

As Traumagel hits the market, it’s more than just a product—it’s a life-saving innovation that has the potential to redefine trauma care. Keep an eye on Cresilon and its groundbreaking tech because this is just the beginning of how biotechnology can help protect and save lives.